Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

NLTX - Neurogene Inc

IEX real time price
3.44
3.440   100.000%

Share volume: 0
Last Updated: Mon 18 Dec 2023 09:30:40 PM CET
Pharmaceutical Preparation Manufacturing : 2.72%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 50%
Dept financing 20%
Liquidity 50%
Performance 35%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
18.17%
6 Months
20.44%
1 Year
20.44%
2 Year
20.44%
Key data
Stock price
$3.44
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$34.69 - $51.42
52 WEEK CHANGE
$20.44
MARKET CAP 
32.799 M
YIELD 
N/A
SHARES OUTSTANDING 
9.398 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
03/18/2024
BETA 
0.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Jonathan G. Drachman
Region: US
Website: neoleukin.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

Neoleukin Therapeutics, Inc. develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.

Recent news